ASTER-GUARDIANS
15.5.2023 15:28:35 CEST | Business Wire | Press release
Margaret Helen Shepherd from UK has been announced as the winner of the Aster Guardians Global Nursing Award 2023 in a prestigious award ceremony held at Queen Elizabeth II Centre in London. The winner was announced by Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare and the award was presented by Professor Jamie Waterall, Deputy Chief Public Health Nurse for the Office of Health Improvement & Disparities at Govt. of UK alongside Ms. Sheila Sobrany – President of Royal College of Nursing; Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare; and Mr. TJ Wilson – Executive Director and Group Head – Governance & Corporate Affairs, Aster DM Healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005491/en/
Margaret Helen Shepherd from the UK - Winner of the Aster Guardians Global Nursing Award 2023 (Photo: AETOSWire)
Launched on International Nurses Day in May 2021 by Aster DM Healthcare, with an aim to recognise the selfless contribution of nurses to millions of patients worldwide, Aster Guardians Global Nursing Award 2023 received an overwhelming response from nurses worldwide with over 52,000 nurses from 202 countries, a 116% growth from the last edition which had received 24,000 applications.
The award ceremony also saw a special video message from Dr. Tedros Adhanom Ghebreyesus – Director General of World Health Organisation being played to congratulate all the finalists and thank Aster DM Healthcare for the initiative.
On winning the award, Nurse Margaret said, “I am deeply humbled and grateful to receive the prestigious Aster Guardians Global Nursing Award. As healthcare professionals, we are privileged to be able to make a positive impact on the lives of our patients, and I feel blessed to be part of such a rewarding profession. This award not only recognises my personal achievements but also highlights the importance of nursing as a critical component of healthcare. Thank you to all my colleagues, mentors, and patients who have supported me throughout my career.”
Margaret has been dedicated to improving diabetes care through better diagnosis. She is the leading nurse for monogenic diabetes in the UK and provides advice to clinicians across the world regarding the management of this condition. She set up a national network of genetic diabetes nurses in 2002 to increase awareness of this condition (which is initially misdiagnosed in 80% of cases, resulting in patients being treated with unnecessary insulin injections). She was one of 70 national NIHR70@70 Senior Nurse Research Leaders (driving innovation and new roles to increase research awareness and engagement within clinical care) and has received the prestigious Florence Nightingale Foundation Leadership Scholarship.
Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “We are honoured to announce Ms Margaret Helen Shepherd from the United Kingdom as the winner of this year's Aster Guardians Global Nursing Award. She has exemplified the highest standards of patient care and dedication that is inspirational, and it deserves global recognition. Each one of the top 10 finalists have done phenomenal work and the Grand Jury had a tough time assessing and selecting the final winner. We are privileged to offer Aster Guardians Global Nursing Award as a platform to share and honor the accomplishments of exceptional nurses from around the globe.”
Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare said, “Aster Guardians Global Nursing Award is a small yet significant expression of gratitude that aligns with this year's International Nurses Day theme, ‘Our Nurses. Our Future’. Nurses ensure that patients receive high-quality care and often go beyond their call of duty to ensure that the right care is provided. This often helps them develop into other areas like research, innovation, mentorship, education, digitization among others as the stories of this year’s finalists and the winner have showcased. We as individuals and organizations must ensure that they receive the recognition they deserve, and this is where initiatives like Aster Guardians Global Nursing Award come into play. As a group, we will continue to support and celebrate the tireless efforts of nurses and put forth their inspiring stories of excellence.”
The rest of the 9 finalists, Cathy Cribben-Pearse from UAE, Christine Mawia Sammy from Kenya, Gloria Ceballo from Panama, Jincy Jerry from Ireland, Lilian Yew Siew Mee from Singapore, Michael Joseph Dino from Philippines, Shanti Teresa Lakra from India, Teresa Fraga from Portugal, and Wilson Fungameza Gwessa from Tanzania were also awarded with a monetary prize.
These nurses were selected through a stringent review process run by Ernst & Young LLP, a panel of Screening-Jury and the Grand Jury.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 30 hospitals, 125 clinics, 496* pharmacies, 20 labs and 157 patient experience centers in seven countries, including India. We reach out to all economic segments in the GCC states through our differentiated healthcare services across the “Aster”, “Medcare” and “Access” brands.
* Including 239 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005491/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom